Loading the security overview…
Where the tokens are
| Quarter | EPS | EPS vs year ago | Revenue | Revenue vs year ago |
|---|---|---|---|---|
| Q2 FY16ended Jun 30, 2016 | $0.00 | −100.0% | $5.60B | −11.2% |
| Q1 FY16ended Mar 31, 2016 | $0.51 | +15.9% | $6.12B | +1.0% |
| Q4 FY15ended Dec 31, 2015 | $0.64 | — | $6.40B | −4.7% |
| Q3 FY15ended Sep 30, 2015 | $0.60 | +200.0% | $5.95B | −10.0% |
| Q2 FY15ended Jun 30, 2015 | $0.55 | +71.9% | $6.31B | −2.3% |
| Q1 FY15ended Mar 31, 2015 | $0.44 | +120.0% | $6.06B | −6.2% |
| Q4 FY14ended Dec 31, 2014 | −$0.25 | — | $6.72B | −1.9% |
| Q3 FY14ended Sep 30, 2014 | $0.20 | −59.2% | $6.61B | +5.7% |
| Q2 FY14ended Jun 30, 2014 | $0.32 | — | $6.45B | — |
| Q1 FY14ended Mar 31, 2014 | $0.20 |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss.
Figures describe AstraZeneca shares, not any token. From Massive's standardised financials and the earnings calendar.
| — |
| $6.46B |
| — |
| Q4 FY13ended Dec 31, 2013 | −$0.42 | — | $6.84B | — |
| Q3 FY13ended Sep 30, 2013 | $0.49 | — | $6.25B | — |